drugset / Trial / NCT02258464
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy
Timeline
- Start
- 2015-03-02
- Primary completion
- 2019-08-13
- Completion
- 2019-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Intravenous |
| Subject | Radium-223 dichloride | Other / unclassified | 0.055 mbq/kg | Intravenous |